Vir Biotechnology Inc
$ 6.00
-1.80%
26 Dec - close price
- Market Cap 834,750,000 USD
- Current Price $ 6.00
- High / Low $ 6.09 / 5.89
- Stock P/E N/A
- Book Value 5.73
- EPS -3.62
- Next Earning Report 2026-02-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.49 %
- 52 Week High 14.45
- 52 Week Low 4.16
About
Vir Biotechnology, Inc. is a clinical-stage immunology firm based in San Francisco, California, dedicated to developing groundbreaking therapeutic solutions for serious infectious diseases. The company utilizes its proprietary technologies and boasts a promising pipeline that features advanced monoclonal antibodies and immunotherapeutics targeting critical unmet medical needs in viral infections, including COVID-19 and influenza. Through strategic collaborations and partnerships, Vir Biotechnology is enhancing its research capabilities, solidifying its role as a key player in the biotechnology landscape while remaining committed to improving global health outcomes.
Analyst Target Price
$17.22
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-07-30 | 2025-04-30 | 2025-02-20 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-04 | 2023-02-23 |
| Reported EPS | -1.17 | -0.8 | -0.88 | -0.76 | -1.56 | -1.02 | -0.48 | -0.86 | -1.22 | -1.45 | -1.06 | -0.76 |
| Estimated EPS | -0.84 | -0.7754 | -0.8433 | -0.89 | -1.05 | -0.9 | -1.05 | -1.01 | -1.21 | -1.2 | -0.87 | -0.39 |
| Surprise | -0.33 | -0.0246 | -0.0367 | 0.13 | -0.51 | -0.12 | 0.57 | 0.15 | -0.01 | -0.25 | -0.19 | -0.37 |
| Surprise Percentage | -39.2857% | -3.1726% | -4.352% | 14.6067% | -48.5714% | -13.3333% | 54.2857% | 14.8515% | -0.8264% | -20.8333% | -21.8391% | -94.8718% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.7363 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VIR
2025-12-18 14:10:06
Latham & Watkins advised Norgine on an exclusive licensing agreement with Vir Biotechnology. Norgine will commercialize tobevibart and elebsiran for Chronic Hepatitis Delta treatment in Europe, Australia, and New Zealand. Vir Biotechnology will receive an initial €55 million reimbursement and up to €495 million in milestone payments, plus tiered royalties on net sales.
2025-12-17 13:10:09
Latham & Watkins advised Norgine, a European specialty pharmaceutical company, on an exclusive licensing agreement with Vir Biotechnology (Nasdaq: VIR). This agreement grants Norgine commercialization rights for tobevibart and elebsiran, a combination therapy for Chronic Hepatitis Delta (CHD), in Europe, Australia, and New Zealand. Vir Biotechnology will receive an initial €55 million, up to €495 million in milestone payments, and tiered royalties on net sales.
2025-12-17 08:10:09
Norgine has announced an exclusive licensing agreement with Vir Biotechnology to commercialize tobevibart and elebsiran for chronic hepatitis delta (CHD) treatment in Europe, Australia, and New Zealand. This partnership aims to address the high unmet medical need for effective CHD treatments. Vir Biotechnology will receive an initial payment of EUR 55 million, with potential regulatory and commercial milestone payments up to EUR 495 million, plus tiered royalties on net sales.
2025-12-16 21:55:55
Vir Biotechnology has licensed exclusive commercial rights for its hepatitis delta combination therapy to Norgine Pharma UK Limited for Europe, Australia, and New Zealand in a deal potentially worth €550 million. Vir will receive an initial €55 million payment and could earn up to €495 million in additional milestones, plus tiered royalties. The agreement involves shared clinical development costs for the ongoing ECLIPSE registrational program, with Vir retaining commercialization rights in other key markets including the United States.
2025-12-16 21:21:54
Vir Biotechnology has granted Norgine an exclusive commercial license for its chronic Hepatitis Delta treatment candidate in Europe, Australia, and New Zealand. This agreement includes a global cost-sharing arrangement for the ongoing ECLIPSE clinical development program. Vir Biotechnology will receive an initial reimbursement payment of EUR 55 million and up to EUR 495 million in clinical, regulatory, and sales milestones.
2025-12-16 21:09:03
Vir Biotechnology has granted Norgine Pharma UK Limited an exclusive license for the commercial rights to its chronic hepatitis delta (CHD) treatment candidate, a combination of tobevibart and elebsiran, in Europe, Australia, and New Zealand. Vir will receive an initial payment of EUR 55 million and will be eligible for up to EUR 495 million in milestones, along with royalties on net sales. The companies will share clinical development costs for the ongoing ECLIPSE registrational program, with Norgine contributing approximately 25% of go-forward external costs, extending Vir Biotechnology's cash runway into Q4 2027.
